الفهرس 
AcknowledgementOnly 14 pages are availabe for public view
 |  | from | 158 |  |  |
| | | from | 158 | | |
Abstract
Our reactions afforded new twenty six compounds that were not mentioned in the literature. Structure elucidation of the newly synthesized compounds was achieved through microanalytical analysis and spectroscopic methods. These new compounds evaluated biologically for their in vitro antitumor activity by the National Cancer Institute (NCI, USA) against tumor cells in full NCI 60 cell panel. The enzyme inhibitory activity of the most active compound was evaluated against topoisomerase 1 (Topo 1), epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor 2 (VEGFR2), where it displayed worthy Topo 1 inhibition activity. Docking study was performed to investigate the recognition profile of the most active compound with Topo 1 enzyme binding site.